Bright Competitors

DRUG Stock  USD 35.78  0.28  0.78%   
Bright Minds Biosciences competes with Revelation Biosciences, Zura Bio, Phio Pharmaceuticals, ZyVersa Therapeutics, and Transcode Therapeutics; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Bright Minds competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Bright Minds to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Bright Minds Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Bright Minds competition on your existing holdings.
  
The current Return On Tangible Assets is estimated to decrease to -1.29. The current Return On Capital Employed is estimated to decrease to -1.35. At this time, Bright Minds' Total Assets are most likely to increase significantly in the upcoming years. The Bright Minds' current Total Current Assets is estimated to increase to about 8.4 M, while Net Tangible Assets are projected to decrease to roughly 8.4 M.
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Bright Minds' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
30.5835.7840.98
Details
Intrinsic
Valuation
LowRealHigh
15.7020.9039.36
Details
Naive
Forecast
LowNextHigh
34.9940.1845.38
Details
0 Analysts
Consensus
LowTargetHigh
4.434.875.41
Details

Bright Minds Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Bright Minds and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Bright and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Bright Minds Biosciences does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
PYXSZURA
ZURAREVB
PYXSREVB
ELEVPYXS
ELEVREVB
ELEVZVSA
  
High negative correlations   
RNAZREVB
APGNELEV
APGNCYTO
ELEVCYTO
APGNEFTR
ELEVEFTR

Risk-Adjusted Indicators

There is a big difference between Bright Stock performing well and Bright Minds Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Bright Minds' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
REVB  5.48 (0.69) 0.00 (1.53) 0.00 
 11.78 
 66.25 
ZURA  4.77 (0.78) 0.00 (0.44) 0.00 
 9.79 
 29.06 
PHIO  11.08  2.19  0.17  0.39  9.61 
 9.40 
 336.29 
ZVSA  4.60 (0.18) 0.00 (0.83) 0.00 
 12.03 
 38.26 
RNAZ  10.21 (1.71) 0.00 (0.50) 0.00 
 28.00 
 94.32 
PYXS  3.25 (0.37) 0.00 (0.34) 0.00 
 6.59 
 17.50 
EFTR  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
CYTO  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
ELEV  4.66  0.16  0.02  0.00  5.09 
 10.00 
 40.61 
APGN  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 

Cross Equities Net Income Analysis

Compare Bright Minds Biosciences and related stocks such as Revelation Biosciences, Zura Bio Limited, and Phio Pharmaceuticals Corp Net Income Over Time
Select Fundamental
Price To Sales RatioPtb Ratio
Days Sales OutstandingBook Value Per Share
Free Cash Flow YieldInvested Capital
Operating Cash Flow Per ShareAverage Payables
Stock Based Compensation To RevenueCapex To Depreciation
Pb RatioEv To Sales
Free Cash Flow Per ShareInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Sales General And Administrative To RevenueAverage Inventory
Research And Ddevelopement To RevenueCapex To Revenue
Cash Per SharePocfratio
Interest CoveragePayout Ratio
Capex To Operating Cash FlowPfcf Ratio
Days Payables OutstandingNet Current Asset Value
Income QualityTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Ev To Free Cash FlowIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Dividend YieldRoic
Payables TurnoverRoe
Return On Tangible AssetsEarnings Yield
Receivables TurnoverShort Term Coverage Ratios
Price Earnings RatioOperating Cycle
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Capital Expenditure Coverage RatioPrice Cash Flow Ratio
Enterprise Value MultipleDebt Ratio
Cash Flow To Debt RatioPrice Sales Ratio
Net Profit MarginGross Profit Margin
Price Fair ValueReturn On Capital Employed
Fixed Asset TurnoverReturn On Assets
Asset TurnoverReturn On Equity
2010201120122013201420152016201720182019202020212022202320242025
REVB4.5 M4.5 M4.5 M4.5 M4.5 M6.2 M8.8 M16.3 M27.6 M(3.6 K)(136.4 K)(12 M)(10.8 M)(120.3 K)(15 B)(14.3 B)
ZURA8.4 M8.4 M8.4 M8.4 M8.4 M8.4 M8.4 M8.4 M8.4 M8.4 M8.4 M8.4 M3.5 M(60.4 M)(54.3 M)(51.6 M)
PHIO(10.2 M)(10.2 M)(12.9 M)(20.9 M)(8.8 M)(10.2 M)(9 M)(12.5 M)(7.4 M)(8.8 M)(8.8 M)(13.2 M)(11.3 M)(10.8 M)(12.4 M)(13.1 M)
ZVSA(13.2 M)(13.2 M)(13.2 M)(13.2 M)(13.2 M)(13.2 M)(13.2 M)(13.2 M)(13.2 M)(13.2 M)(13.2 M)(8.9 M)(759.1 M)(98.3 M)(88.5 M)(92.9 M)
RNAZ(764.1 K)(764.1 K)(764.1 K)(764.1 K)(764.1 K)(764.1 K)(764.1 K)(764.1 K)(764.1 K)(764.1 K)(2.7 M)(6.9 M)(35.1 M)(18.5 M)(16.7 M)(17.5 M)
PYXS(2.7 M)(2.7 M)(2.7 M)(2.7 M)(2.7 M)(2.7 M)(2.7 M)(2.7 M)(2.7 M)(2.7 M)(12.8 M)(81.5 M)(118 M)(73.8 M)(66.4 M)(69.7 M)
ELEV(5.9 M)(5.9 M)(5.9 M)(5.9 M)(5.9 M)(5.9 M)(5.9 M)(5.9 M)(5.9 M)(5.9 M)(17.3 M)(32 M)(95.1 M)(45.7 M)(44.5 M)(46.7 M)
IMMX(972.8 K)(972.8 K)(972.8 K)(972.8 K)(972.8 K)(972.8 K)(972.8 K)(972.8 K)(972.8 K)(972.8 K)(1.1 M)(24.4 M)(8.2 M)(15.4 M)(13.9 M)(14.6 M)
ADTX(213 K)(213 K)(213 K)(213 K)(213 K)(213 K)(213 K)(213 K)(5.7 M)(5.8 M)(9.5 M)(48.3 M)(28.2 M)(32.4 M)(29.1 M)(30.6 M)
DRMA(5 M)(5 M)(5 M)(5 M)(5 M)(5 M)(5 M)(5 M)(5 M)(5 M)(3.4 M)(7.9 M)(9.6 M)(7.8 M)(7 M)(7.4 M)
UNCY(2.3 M)(2.3 M)(2.3 M)(2.3 M)(2.3 M)(2.3 M)(2.3 M)(2.3 M)(2.3 M)(2.3 M)(2.5 M)(10.6 M)(18.1 M)(30.5 M)(27.5 M)(26.1 M)

Bright Minds Biosciences and related stocks such as Revelation Biosciences, Zura Bio Limited, and Phio Pharmaceuticals Corp Net Income description

Net income is one of the most important fundamental items in finance. It plays a large role in Bright Minds Biosciences financial statement analysis. It represents the amount of money remaining after all of Bright Minds Biosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Bright Minds Competitive Analysis

The better you understand Bright Minds competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Bright Minds' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Bright Minds' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
DRUG REVB ZURA PHIO ZVSA RNAZ PYXS ELEV IMMX ADTX
 0.78 
 35.78 
Bright
 3.98 
 3.40 
Revelation
 18.52 
 1.28 
Zura
 3.01 
 1.29 
Phio
 1.25 
 0.79 
ZyVersa
 5.41 
 0.78 
Transcode
 3.74 
 1.11 
Pyxis
 6.00 
 0.53 
Elevation
 4.43 
 1.65 
Immix
 0.50 
 0.02 
Aditxt
Market Volatility
(90 Days Market Risk)
Market Performance
(90 Days Performance)
Odds of Financial Distress
(Probability Of Bankruptcy)
Current Valuation
(Equity Enterprise Value)
Buy or Sell Advice
(Average Analysts Consensus)
Trade Advice
(90 Days Macroaxis Advice)
Current Ratio
Net Asset
EBITDA
Current Valuation
Price To Book
Operating Margin
Retained Earnings
Current Asset
Beta
Number Of Employees
Shares Outstanding
Cash Flow From Operations
Total Debt
Return On Equity
Z Score
Return On Asset
Number Of Shares Shorted
Book Value Per Share
Current Liabilities
Total Asset
Short Ratio
Target Price
Debt To Equity
Shares Owned By Institutions
Market Capitalization
Price To Earning
Price To Earnings To Growth
Price To Sales
Net Income
Earnings Per Share
Shares Owned By Insiders
Revenue
Working Capital
Cash And Equivalents
Cash Per Share
Gross Profit
Day Typical Price
Accumulation Distribution
Market Facilitation Index
Daily Balance Of Power
Period Momentum Indicator
Rate Of Daily Change
Day Median Price
Price Action Indicator
Coefficient Of Variation
Mean Deviation
Jensen Alpha
Total Risk Alpha
Sortino Ratio
Downside Variance
Standard Deviation
Kurtosis
Potential Upside
Treynor Ratio
Maximum Drawdown
Variance
Market Risk Adjusted Performance
Risk Adjusted Performance
Skewness
Semi Deviation
Information Ratio
Value At Risk
Expected Short fall
Downside Deviation
Semi Variance

Bright Minds Competition Performance Charts

Five steps to successful analysis of Bright Minds Competition

Bright Minds' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Bright Minds Biosciences in relation to its competition. Bright Minds' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Bright Minds in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Bright Minds' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Bright Minds Biosciences, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Bright Minds position

In addition to having Bright Minds in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Natural Foods Thematic Idea Now

Natural Foods
Natural Foods Theme
Companies producing natural foods including dairy products and different types of meets. The Natural Foods theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Natural Foods Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Bright Minds Biosciences is a strong investment it is important to analyze Bright Minds' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bright Minds' future performance. For an informed investment choice regarding Bright Stock, refer to the following important reports:
Check out Bright Minds Correlation with its peers.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bright Minds. If investors know Bright will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bright Minds listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.45)
Return On Assets
(0.29)
Return On Equity
(0.52)
The market value of Bright Minds Biosciences is measured differently than its book value, which is the value of Bright that is recorded on the company's balance sheet. Investors also form their own opinion of Bright Minds' value that differs from its market value or its book value, called intrinsic value, which is Bright Minds' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bright Minds' market value can be influenced by many factors that don't directly affect Bright Minds' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bright Minds' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bright Minds is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bright Minds' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.